Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Martina Sanlorenzo, Igor Vujic, Adil Daud, +7

JAMA Dermatology

Updated<scp>S2</scp>K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>)

Luca Borradori, Nina van Beek, Claudio Feliciani, +52

Journal of the European Academy of Dermatology and Venereology

DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics

Alfonso Latorre, Christian Posch, Yolanda Garcimartín, +8

Nanoscale

NanoparticlesNanotherapeuticsEngineeringTargeted DeliveryBiomedical Engineering +14

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma

Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, +10

Journal of the American Academy of Dermatology

Skin CancerComparative ProfileMedicinePhotocarcinogenesisMelanoma +4

The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients

Christian Posch, Babak Itzinger-Monshi, Tamara Quint, +3

Journal of the American Academy of Dermatology

Wide Local ExcisionSevere Hidradenitis SuppurativaRetrospective AnalysisClinical DermatologySurgery +3

Metformin and trametinib have synergistic effects on cell viability and tumor growth in<i>NRAS</i>mutant cancer

Igor Vujic, Martina Sanlorenzo, Christian Posch, +7

Oncotarget

Efficacy of intravenous immunoglobulins in livedoid vasculopathy: Long-term follow-up of 11 patients

Babak Itzinger-Monshi, Christian Posch, Igor Vujic, +3

Journal of the American Academy of Dermatology

RheumatologyVasculitisImmunologyIntravenous ImmunoglobulinsTransplant Arteriopathy +4

Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma

Christian Posch, Brian D. Cholewa, Igor Vujic, +9

Journal of Investigative Dermatology

MedicineMelanomaImmune Checkpoint InhibitorCancer BiologyNras Mutant Melanoma +5

Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*

Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, +35

British Journal of Dermatology

Apremilast in psoriasis – a prospective real‐world study

Igor Vujic, Robert Herman, Martina Sanlorenzo, +4

Journal of the European Academy of Dermatology and Venereology